Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of HR011408 vs NovoRapid in Healthy Subjects
NCT05737576Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in diabetes mellitus (DM) (6 cohorts), sponsored by Hengrui. Primary endpoint: Area under the concentration-time curve (AUC0-0.5h). Started Mar 2023; status: completed.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05737576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737576.